20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
21:23 , May 3, 2019 |  BioCentury  |  Emerging Company Profile

Vineti: Keeping cell therapies on track

Drawing on its experience with CAR T cell therapies, Vineti has developed a cloud-based software platform that standardizes processes and drives down costs in the supply chain for personalized medicines. According to Vineti Inc. CEO...
14:07 , Apr 11, 2019 |  BC Extra  |  Financial News

Autolus follows up CAR T data with $101M raise

Days after announcing the first response rates from a Phase I/II trial of CAR T cell therapy AUTO1, Autolus raised $100.8 million in a follow-on offering. Late Wednesday, Autolus Therapeutics plc (NASDAQ:AUTL) sold 4.2 million...
17:41 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Autolus' dual targeting CAR T safe in Phase I/II data for hematological malignancies

Autolus Therapeutics plc (NASDAQ:AUTL) reported preliminary data from a pair of open-label, U.K. Phase I/II trials showing that AUTO3 had a manageable safety profile and led to responses among patients with hematological malignancies. AUTO3 comprises...
18:26 , Dec 5, 2018 |  BC Extra  |  Politics & Policy

U.K. unveils second life sciences deal, headlined by UCB investment

Just days ahead of a Parliamentary vote on a Brexit deal, the U.K. government announced Wednesday a second deal for life sciences that comprises mostly industry investment into the U.K. spearheaded by a £1 billion...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
22:38 , Nov 1, 2018 |  BC Extra  |  Company News

Management tracks: CuraSen names Vargas CMO; plus Sosei, Casebia

Neurodegenerative disease start-up CuraSen Therapeutics Inc. (San Mateo, Calif.) hired Gabriel Vargas as its first CMO. Vargas led early development of migraine prophylactic Aimovig erenumab at Amgen Inc. (NASDAQ:AMGN), where he was most recently executive...
19:57 , Oct 18, 2018 |  BC Extra  |  Company News

Management tracks: Autolus, Bayer, Cambridge Allergy

T cell cancer therapy company Autolus Therapeutics plc (NASDAQ:AUTL) hired Adam Hacker as SVP for regulatory affairs and quality, a newly created position. Previously, he was VP, head of vaccines and scientific innovation projects, global...
23:10 , Oct 17, 2018 |  BC Extra  |  Company News

Management tracks: Ziopharm, Merck

Immunotherapy company Ziopharm Oncology Inc. (NASDAQ:ZIOP) said CMO and EVP of R&D Francois Lebel will step down, effective Oct. 26. Merck & Co. Inc. (NYSE:MRK) hired Jim Scholefield as chief information and digital officer. He...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...